Publications

Adenosine | Peroxynitrite | Flagellin | PARP | Other|

Use the links above to browse the publications by technology

Selected Inotek publications

Abdelkarim GE, Gertz K, Harms C, Katchanov J, Dirnagl U, Szabó C, Endres M. 2001. Protective effects of PJ34, a novel, potent inhibitor of poly (ADP-ribose) polymerase in in vitro and in vivo models of stroke. Int J Mol Med 7:255-260.

Cheng CL, Johnson SP, Keir ST, Quinn JA, Ali-Osman F, Szabo F, Szabo C, Li H, Salzman AL, Dolan ME, Modrich P, Bigner DD, Friedman HS.  2005. Poly (ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair -deficit malignant glioma xenograft.  Mol Cancer Ther 4(9):1364-8.

Goldfarb RD, Marton A, Szabó E, Virág L, Glock D, McCarthy R, Parrillo JE, Szabó C. 2002. Protective effect of a novel, potent inhibitor of poly (adenosine 5’ - diphosphate-ribose) synthetase in a porcine model of severe bacterial sepsis. Crit Care Med 30(5):974-980.

Jagtap P, Szabó C.  2005. Poly (ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nature Reviews Drug Discovery 4(5): 421-440.

Khan TA, Ruel M, Bianchi C, Voisine P, Komjáti K, Szabó C, Sellke FW. 2003. Poly (ADP-Ribose) synthetase inhibition improves postischemic myocardial function after cardioplegia-cardiopulmonary bypass. J Am Coll Surg 197:270-277.

Komjati K, Besson VC, Szabo C. 2005.  Poly (ADP-ribose) polymerase inhibitors as potential therapeutic agents in stroke and neurotrauma.  Curr Drug Targets CNS Neurol Disord 4(2):179-94.

Mabley JG, Pacher P, Liaudet L, Soriano FG, Haskó G, Marton A, Szabó C, Salzman AL. 2003. Inosine reduces inflammation and improves survival in a murine model of colitis. Am J Physiol 284:G138-144.

Naidu BV, Fraga C, Salzman AL, Szabó C, Verrier ED, Mulligan MS. 2003. Critical role of reactive nitrogen species in lung ischemia-reperfusion injury. J Heart Lung Transplant 22:784-93.

Scott GS, Hake P, Kean RB, Virág L, Szabó C, Hooper DC. 2001. Role of poly (ADP-ribose) synthetase activation in the development of experimental allergic encephalomyelitis. J Neuroimunol 117:78-86.

Shimoda K, Murakami K, Enkhbaatar P, Traber LD, Cox RA, Hawkins HK, Schmalstieg FC, Komjati K, Mabley JG, Szabó C, Salzman AL, Traber DL. 2003. Effect of poly (ADP-ribose) synthetase inhibition on burn and smoke inhalation injury in the sheep. Am J Physiol 285:L240-L249.

Soriano FG, Mabley JG, Pacher P, Liaudet L, Szabó C. 2001. Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly (ADP-ribose) polymerase. Circ Res 89:684-691.

Soriano FG, Virág L, Jagtap P, Szabó É, Mabley JG, Liaudet L, Marton A, Hoyt DG, Murthy KGK, Salzman AL, Southan GJ, Szabó C.  2001. Diabetic endothelial dysfunction: the role of poly (ADP-ribose) polymerase activation.  Nature Medicine 7(1):108-113.

Szabo C.  2005. Cardioprotective effects of poly (ADP-ribose) polymerase inhibition. Pharmacol Res 52(1):34-43.

Szabo C.  2005. Pharmacological inhibition of poly (ADP-ribose) polymerase in cardiovascular disorders: future directions.  Curr Vasc Pharmacol 3(3):301-3.

Szabo C. 2005.  Roles of poly (ADP-ribose) polymerase activation in the pathogenesis of diabetes mellitus and its complications.  Pharmacol Res 52(1): 60-71.

Szabo G, Soos P, Bahrle S, Zsengeller Z, Flechtenmacher C, Hagl S, Szabo C. 2004. Role of poly (ADP-ribose) polymerase activation in the pathogenesis of cardiopulmonary dysfunction in a canine model of cardiopulmonary bypass. European Journal of Cardio-thoracic Surgery 25:825-832

Szabó C, Zanchi A, Komjáti K, Pacher P, Krolewski AS, Quist WC, Horton ES, LoGerfo FW, Veves A. 2002. Poly (ADP-Ribose) polymerase is activated in subjects at risk of developing Type 2 diabetes and is associated with impaired vascular reactivity. Circulation 106:2680-6.